Prophylactic and therapeutic benefits of COX-2 inhibitor on motility dysfunction in bowel obstruction: Roles of PGE 2 and EP receptors

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 302, Issue 2, 2012, Pages

  Lin, You Min ^a   Sarna, Sushil K ^a   Shi, Xuan Zheng ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Colon; E prostanoid; Mechanical stretch; Mechanotranscription; NS 398; Prostaglandin E 2; Smooth muscle

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTANOID RECEPTOR; RECEPTOR SUBTYPE; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON MOTILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; INTESTINE MUSCLE; INTESTINE OBSTRUCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE CONTRACTILITY; WESTERN BLOTTING;

ANIMALS; COLON; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; GASTROINTESTINAL MOTILITY; INTESTINAL OBSTRUCTION; NITROBENZENES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E; SULFONAMIDES;

EID: 84855298346     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00326.2011     Document Type: Article

References (55)

1. Adam M, Boie Y, Rushmore TH, Muller G, Bastien L, McKee KT, Metters KM, Abramovitz M. Cloning and expression of three isoforms of the human EP3 prostanoid receptor. FEBS Lett 338: 170-174, 1994.
2. Adam RM, Eaton SH, Estrada C, Nimgaonkar A, Shih SC, Smith LE, Kohane IS, Bägli D, Freeman MR. Mechanical stretch is a highly selective regulator of gene expression in human bladder smooth muscle cells. Physiol Genomics 20: 36-44, 2004.
3. Barbara G, De Giorgio R, Deng Y, Vallance B, Blennerhassett P, Collins SM. Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology 120: 1729-1736, 2001.
4. Bassil AK, Borman RA, Jarvie EM, McArthur-Wilson RJ, Thangiah R, Sung EZH, Lee K, Sange GJ. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 154: 126-135, 2008.
5. Bertoni S, Gabella G, Ghizzardi P, Ballabeni V, Impicciatore M, Lagrasta C, Arcari ML, Barocelli E. Motor response of rat hypertrophic intestine following chronic obstruction. Neurogastroenterol Motil 16: 365-374, 2004.
6. Botella A, Delvaux M, Fioramonti J, Frexinos J, Bueno L. Stimulatory (EP1 and EP3) and inhibitory (EP2) prostaglandin E2 receptors in isolated ileal smooth muscle cells. Eur J Pharmacol 237: 131-137, 1993.
7. Botella A, Delvaux M, Fioramonti J, Frexinos J, Bueno L. Receptor subtypes involved in dual effects induced by prostaglandin E2 in circular smooth muscle from dog colon. J Pharmacol Exp Ther 273: 1008-1014, 1995.
8. Cong P, Pricolo V, Biancani P, Behar J. Abnormalities of prostaglandins and cyclooxygenase enzymes in female patients with slow transit constipation. Gastroenterology 133: 445-453, 2007.
9. Ferrario A, Fisher AM, Rucher N, Gomer CJ. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis anddecreasing in vivo inflammatory and angiogenic factors. Cancer Res 65: 2551-2556, 2005.
10. Fornai M, Blandizzi C, Colucci R, Antonioli L, Bernardini N, Seqnani C, Baraqatti B, Baroqi S, Berti P, Spisni R, Del Tacca M. Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut 54: 608-616, 2005.
11. Fraser ID, Condon RE, Schulte WJ, DeCrosse JJ, Cowles VE. Intestinal motility changes in experimental large bowel obstruction. Surgery 87: 677-682, 1980.
12. Gabella G. Hypertrophy of visceral smooth muscle. Anat Embryol 182: 409-424, 1990.
13. Goulet O, Ruemmele F. Causes and management of intestinal failure in children. Gastroenterology 130, Suppl 1: S16-S28, 2006.
14. Grosfeld JL, Rescorla FJ. Duodenal atresia and stenosis: reassessment of treatment and outcome based on antenatal diagnosis, pathologic variance, and long-term follow-up. World J Surg 17: 301-309, 1993.
15. Kanefsky J, Lenburg M, Hai CM. Cholinergic receptor and cyclic stretch-mediated inflammatory gene expression in intact ASM. Am J Respir Cell Mol Biol 34: 417-425, 2006.
16. Kim HY, Kim JH, Jung SE, Lee SC, Park KW, Kim WK. Surgical treatment and prognosis of chronic intestinal pseudo-obstruction in children. J Pediatr Surg 40: 1753-1759, 2005.
17. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 122: 217-224, 1997.
18. Kita K, Takahashi K, Ohashi Takasuka H Y, Aihara E, Takeuchi K. Phosphodiesterase isozymes involved in regulation of HCO3-secretion in isolated mouse stomach in vitro. J Pharmacol Exp Ther 326: 889-896, 2008.
19. Krause W, DuBois RN. Eicosanoids and the large intestine. Prostaglandins Other Lipid Mediat 61: 145-61, 2000.
20. Krause W, Dubois RN. The Molecular basis for prevention of colorectal cancer. Clin Colorectal Cancer 1: 47-54, 2001.
21. Li F, Sarna SK, Shi XZ. Intracellular signaling mechanism of stretchinduced expression of COX-2 in colonic smooth muscle cells (Abstract). Gastroenterology 140: S120, 2011.
22. Lin YM, Li F, Sarna SK, Shi XZ. Mechanotranscription is a common pathophysiological mechanism throughout the gastrointestinal tract (Abstract). Gastroenterology 140: S706, 2011.
23. Linden DR, Sharkey KA, Ho W, Mawe GM. Cyclooxygenase-2 contributes to dysmotility and enhanced excitability of myenteric AH neurones in the inflamed guinea pig distal colon. J Physiol 557: 191-205, 2004.
24. Lugo B, Ford HR, Grishin A. Molecular signaling in necrotizing enterocolitis: regulation of intestinal COX-2 expression. J Pediatr Surg 42: 1165-1171, 2007.
25. Matsuo M, Yoshida N, Zaitsu M, Ishii K, Hamasaki Y. Inhibition of human glioma cell growth by a PHS-2 inhibitor, NS398, and a prostaglandin E receptor subtype EP1-selective antagonist, SC51089. J Neurooncol 66: 285-92, 2004.
26. Menezes M, Corbally M, Puri P. Long-term results of bowel function after treatment for Hirschsprung's disease: a 29-year review. Pediatr Surg Int 22: 987-990, 2006.
27. Mohajer B, Ma TY. Eicosanoids and the small intestine. Prostaglandins Other Lipid Mediat 61: 125-143, 2000.
28. Narumiya S, Suqimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, functions. Physiol Rev 79: 1193-1226, 1999.
29. Natarajan R, Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol 24: 1542-1548, 2004.
30. Negishi M, Sigimoto Y, 1995. Negishi M, Sugimoto Y, Namba T, Irie A, Narumiya S, Ichikawa A. Signal transductions of three isoforms of mouse prostaglandin E receptor EP3 subtype. Adv Prostaglandin Thromboxane Leukot Res 23: 255-257, 1995.
31. Ohman U. Prognosis in patients with obstructing colorectal carcinoma. Am J Surg 143: 742-747, 1982.
32. Piazuelo E, Jimenez P, Strunk M, Santander S, Garcia A, Esteva F, Lanas A. Effects of selective PGE2 receptor antagnosis in esophageal adenocarcinoma cells derived from Barrett's esophagus. Prostaglandins Other Lipid Mediat 81: 150-161, 2006.
33. Porcher C, Horowitz B, Ward SM, Sanders KM. Constitutive and functional expression of cyclooxygenase 2 in the murine proximal colon. Neurogastroenterol Motil 16: 785-799, 2004.
34. Prihoda M, Flatt A, Summers RW. Mechanisms of motility changes during acute intestinal obstruction in the dog. Am J Physiol Gastrointest Liver Physiol 247: G37-G42, 1984.
35. Russell JC, Welch JP. Pathophysiology of bowel obstruction. In: Bowel Obstruction, ed. JP Welch. Philadelphia, PA: W. B. Saunders, 1990, pp. 28-58.
36. Sanders KM. Evidence that prostaglandins are local regulatory agents in canine ileal circular muscle. Am J Physiol Gastrointest Liver Physiol 246: G361-G371, 1984.
37. Sarna SK, Shi XZ. Function and regulation of colonic contractions in health and disease. In: Physiology of the Gastrointestinal Tract, ed. LR Johnson. Amsterdam: Elsevier Academic, 2006, 965-993.
38. Schwarz NT, Kalff JC, Turler A, Engel BM, Watkins SC, Billiar TR, Bauer AJ. Prostanoid production via COX-2 as a causative mechanism of rodent postoperative ileus. Gastroenterology 121: 1354-1371, 2001.
39. Shi XZ, Lindholm PF, Sarna SK. NF-kappa B activation by oxidative stress and inflammation suppresses contractility in colonic circular smooth muscle cells. Gastroenterology 124: 1369-1380, 2003.
40. Shi XZ, Pazdrak K, Saada N, Dai B, Palade P, Sarna SK. Negative transcriptional regulation of human colonic smooth muscle Cav1.2 channels by p50 and p65 subunits of nuclear factor-kappaB. Gastroenterology 129: 1518-1532, 2005.
41. Shi XZ, Sarna SK. Transcriptional regulation of inflammatory mediators secreted by human colonic circular smooth muscle cells. Am J Physiol Gastrointest Liver Physiol 289: G274-G284, 2005.
42. Shi XZ, Sarna SK. Gene therapy with VIP, VIP receptor agonists and VIP receptor antagonists: a novel approach to designing pro-motility and anti-motility agents. Am J Physiol Gastrointest Liver Physiol 295: G187-G196, 2008.
43. Shi XZ, Lin YM, Powell DR, Sarna SK. Pathophysiology of motility dysfunction in bowel obstruction: Role of stretch-induced COX-2. Am J Physiol Gastrointest Liver Physiol 300: G99-G108, 2011.
44. Silen W. Acute intestinal obstruction. In: Harrison's Principles of Internal Medicine (16th Edition), ed. E Braunwald, KJ Isselbacher, RG Petersdorf, JD Wilson, JB Martin, AS Fauci. New York, NY: McGraw-Hill, 2005, pp. 1803-1805.
45. Smid SD, Svensson KM. Inhibition of COX-2 and EP1 receptor antagonism reduces human colonic longitudinal muscle contractility in vitro. Prostaglandins Other Lipid Mediat 88: 117-121, 2009.
46. Summers RW. Approach to the patient with ileus and obstruction. In: Textbook of Gastroenterology, ed. Yamada, Alpers, Laine, Owyang, and Powell. Philadelphia, PA: Lippincott Williams & Wilkins, 1999, pp. 842-858.
47. Thompson JS. Overview of etiology and management of intestinal failure. Gastroenterology 130, Suppl 1: S3-S4, 2006.
48. Tokanovic S, White CW, Malone DT, Exintaris B, Ventura S. Characterization of the prostanoid receptor mediating inhibition of smooth muscle contractility in the rat prostate gland. Naunyn Schmiedebergs Arch Pharmacol 381: 321-328, 2010.
49. Wallace JL. COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation. Scientific World Journal 6: 577-588, 2006.
50. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29: 781-788, 2010.
51. Welch JP. General considerations and mortality. In: Bowel Obstruction, ed. JP Welch. Philadelphia, PA: Saunders, 1990, pp. 59-95.
52. Wolmark N, Wieand HS, Rockette HE, Fisher B, Glass A, Lawrence W, Lerner H, Cruz AB, Volk H, Shibata H, Evans J, Prager D, other NSABP Investigators. The prognostic significance of tumor location and bowel obstruction in dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg 198: 743-752, 1983.
53. Won KJ, Suzuki T, Hori M, Ozaki H. Motility disorder in experimentally obstructed intestine: relationship between muscularis inflammation and disruption of the ICC network. Neurogastroenterol Motil 18: 53-61, 2006.
54. Yang C, Kwan YW, Au AL, Poon CC, Zhang Q, Chan SW, Lee SM, Leung GP. 14,15-Epoxyeicosatrienoic acid induces vasorelaxation through the prostaglandin EP(2) receptors in rat mesenteric artery. Prostaglandins Other Lipid Mediat 93: 44-51, 2010.
55. Xiao ZL, Biancani P, Behar J. Effects of progesterone on motility and prostaglandin levels in the distal guinea pig colon. Am J Physiol Gastrointest Liver Physiol 297: G886-G893, 2009.